Đánh giá kinh tế của xét nghiệm di truyền dòng germline cho ung thư vú ở các quốc gia có thu nhập thấp và trung bình: một đánh giá hệ thống

Malayisa Source. Globocan 2020 [Internet]. The Global Cancer Observatory. 2021 [cited 13 May 2023]. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. Cancer J Clin. 2019;69(6):438–51. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75. Verhoeven D, Kaufman CS, Siesling S, Mansel R. Breast cancer: global quality care. Oxford University Press, USA; 2019. El Saghir NS, Adebamowo CA, Anderson BO, Carlson RW, Bird PA, Corbex M, et al. Breast cancer management in low resource countries (LRCs): consensus statement from the breast Health Global Initiative. Breast. 2011;20:3–S11. Economopoulou P, Dimitriadis G, Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev. 2015;41(1):1–8. Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of breast surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23:3100–5. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668–77. Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J, Patócs AB, et al. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet. 2021;64(12):104350. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–62. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255–66. Chlebowski RT. Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med. 2002;53(1):519–40. Khoury MJ. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med. 2003;5(4):261–8. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674. Network NCC. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic (version 3.2023). 2023. England N. Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations. England, UK: NHS England Specialised Services Clinical Reference Group for Medical Genetics; 2015. Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. JNCI: J Natl Cancer Inst. 2018;110(7):714–25. Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, et al. Germline mutations in Cancer susceptibility genes in a large series of unselected breast Cancer PatientsMutations in Cancer susceptibility genes in breast Cancer. Clin Cancer Res. 2017;23(20):6113–9. Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453. Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, et al. Rapid genetic testing for BRCA1 and BRCA2 mutations at the time of breast cancer diagnosis: an observational study. Ann Surg Oncol. 2021;28:2219–26. De Silva DL, Stafford L, Skandarajah AR, Sinclair M, Devereux L, Hogg K et al. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. Med J Aust. 2023. Manchanda R, Gaba F. A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm. BJOG: Int J Obstet Gynecol. 2019. Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet Sci. 2019;21(9):1958–68. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci. 2014;111(39):14205–10. Norum J, Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Undlien DE, et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO open. 2018;3(3):e000328. D’Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, et al. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med. 2016;18(12):1171–80. Koldehoff A, Danner M, Civello D, Rhiem K, Stock S, Muller D. Cost-effectiveness of targeted genetic testing for breast and ovarian Cancer: a systematic review. Value Health. 2021;24(2):303–12. Meshkani Z, Aboutorabi A, Moradi N, Langarizadeh M, Motlagh AG. Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. Hered Cancer Clin Pract. 2021;19(1):35. Tao Y, Liu ST, Wang W. BRCA 1/2 jiyin jiance zai ruxianai fangzhizhong de weisheng jingjixue pingjia xitong zongsu [A systematic review of the health economics evaluation of BRCA 1/2 gene detection in the prevention and treatment of breast cancer]. Zhongguo Weisheng Ziyuan. 2022;25(6):742–5564. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group* t. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. World Bank Country and Lending Groups [Internet]. 2023 [cited 13 May 2023]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51–9. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31. Wu H-l, Luo Z-y, He Z-l, Gong Y, Mo M, Ming W-k, et al. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. Br J Cancer. 2023;128(4):638–46. Lim KK, Yoon SY, Mohd Taib NA, Shabaruddin FH, Dahlui M, Woo YL, et al. Is BRCA mutation testing cost effective for early stage breast cancer patients compared to routine clinical surveillance? The case of an upper middle-income country in Asia. Appl Health Econ Health Policy. 2018;16:395–406. Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, et al. Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems. Cancers. 2020;12(7):1929. Sun L, Cui B, Wei X, Sadique Z, Yang L, Manchanda R, et al. Cost-effectiveness of genetic testing for all women diagnosed with breast cancer in China. Cancers. 2022;14(7):1839. Simoes Correa-Galendi J, del Pilar Estevez Diz M, Stock S, Müller D. Economic modelling of screen-and-treat strategies for Brazilian women at risk of hereditary breast and ovarian cancer. Appl Health Econ Health Policy. 2021;19:97–109. Lourencao M, Simoes Correa Galendi J, Galvão HCR, Antoniazzi AP, Grasel RS, Carvalho AL, et al. Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies: using real-world data from an upper-middle income country. Front Oncol. 2022;12:951310. Lerner-Ellis J, Khalouei S, Sopik V, Narod SA. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Rev Anticancer Ther. 2015;15(11):1315–26. Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H. The role of genetic testing in patients with breast cancer: a review. JAMA Surg. 2017;152(6):589–94. Feliubadaló L, Lopez-Doriga A, Castellsagué E, Del Valle J, Menéndez M, Tornero E, et al. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet. 2013;21(8):864–70. Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D. Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel. Cancer Prev Res. 2021;14(4):455–62. Fountzilas C, Kaklamani VG. Multi-gene panel testing in breast cancer management. Optimizing Breast Cancer Manage. 2018:121–40. Neben CL, Zimmer AD, Stedden W, van den Akker J, O’Connor R, Chan RC, et al. Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn. 2019;21(4):646–57. Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A-R, et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precision Oncol. 2017;1:1–12. Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ. A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health. 2017;20(4):547–55. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222–33. Catana A, Apostu AP, Antemie R-G. Multi gene panel testing for hereditary breast cancer-is it ready to be used? Med Pharm Rep. 2019;92(3):220. Lim YX, Lim ZL, Ho PJ, Li J. Breast cancer in Asia: incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. Cancers. 2022;14(17):4218. Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800. Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history–based testing. J Natl Cancer Inst. 2015;107(1):dju380. Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG, et al. Cost-effectiveness of population based BRCA testing with varying Ashkenazi jewish ancestry. Am J Obstet Gynecol. 2017;217(5):578. e1-. e12. Hafertepen L, Pastorino A, Morman N, Snow J, Halaharvi D, Byrne L, et al. Barriers to genetic testing in newly diagnosed breast cancer patients: do surgeons limit testing? Am J Surg. 2017;214(1):105–10. Kuntz K, Sainfort F, Butler M, Taylor B, Kulasingam S, Gregory S, et al. Decision and simulation modeling alongside systematic reviews. Decision and Simulation modeling in systematic reviews [Internet]. Agency for Healthcare Research and Quality (US); 2013. Graves J, Garbett S, Zhou Z, Schildcrout JS, Peterson J. Comparison of decision modeling approaches for health technology and policy evaluation. Med Decis Making. 2021;41(4):453–64. Zischke J, White N, Gordon L. Accounting for Intergenerational Cascade Testing in Economic Evaluations of Clinical Genomics: a scoping review. Value Health. 2022;25(6):944–53. Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, et al. Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States. JAMA Netw open. 2020;3(10):e2022874–e. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15–21. Simões Corrêa Galendi J, Kautz-Freimuth S, Stock S, Müller D. Uptake rates of risk-reducing surgeries for women at increased risk of hereditary breast and ovarian Cancer applied to cost-effectiveness analyses: a scoping systematic review. Cancers. 2022;14(7):1786. Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA. A Microsimulation Model for evaluating the effectiveness of Cancer Risk management for BRCA pathogenic variant carriers: miBRovaCAre. Value Health. 2019;22(8):854–62. Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo‐oophorectomy in BRCA carriers and women of unknown mutation status. BJOG: Int J Obstet Gynecol. 2011;118(7):814–24. Esmail L, Moore E, Rein A. Evaluating patient and stakeholder engagement in research: moving from theory to practice. J Comp Eff Res. 2015;4(2):133–45. Brett J, Staniszewska S, Mockford C, Herron-Marx S, Hughes J, Tysall C, et al. Mapping the impact of patient and public involvement on health and social care research: a systematic review. Health Expect. 2014;17(5):637–50. Teppala S, Hodgkinson B, Hayes S, Scuffham P, Tuffaha H. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. J Med Econ. 2023;26(1):19–33. Terkola R, Antoñanzas F, Postma M. Economic evaluation of personalized medicine: a call for real-world data. Springer; 2017. pp. 1065–7.